Tachyben solution for injections 5mg/ml, 5ml x 5 ampoules — Made in Austria — Free Delivery

Indications

Hypertensive crisis, severe forms of hypertension, refractory hypertension, controlled (controlled) decrease in blood pressure with its increase during and / or after surgery.

Application

Hypertensive crisis, severe forms of hypertension, refractory hypertension.

IV injections of 10–50 mg of urapidil are administered intravenously slowly with constant monitoring of blood pressure. A decrease in blood pressure can be expected within 5 minutes after injection. Depending on the clinical effect, repeated administration of the preparation is possible (at a dose of 10–50 mg of urapidil).

In/in drip infusion or infusion with a perfusator: to maintain blood pressure at the level achieved by injection, the preparation is administered by infusion.

Preparation of solution for infusion

IV drip infusion: 250 mg of urapidil (50 ml of the preparation) is added to 500 ml of 0.9% sodium chloride solution for injection or 5% or 10% glucose solution for infusion.

IV infusion using a perfusator: 100 mg of urapidil (20 ml of the preparation) are drawn into a perfusator and diluted to a volume of 50 ml with 0.9% sodium chloride solution for injection or 5% or 10% glucose solution for infusion.

The preparation is diluted under aseptic conditions.

Before the introduction, it is necessary to visually check the color of the solution and the presence of mechanical impurities in it. Only transparent and colorless solutions that do not contain mechanical impurities can be used.

The concentration of the solution for infusion should not exceed 4 mg urapidil / ml.

The rate of administration is adjusted depending on the individual response to blood pressure. The recommended rate of administration is no more than 2 mg / min.

Maintenance dose - an average of 9 mg / h. When diluting 50 ml of the preparation  (250 mg of urapidil) in 500 ml of a solvent, 1 mg \u003d 44 drops \u003d 2.2 ml.

Managed (controlled) decrease in blood pressure with its increase during and / or after surgery.

Dosing regimen

Note. The preparation is administered intravenously to patients who are in the supine position. The dose may be administered by one or more injections or by slow infusion. Injections can be combined with subsequent slow infusion.

Treatment of elderly patients. In elderly patients, antihypertensive preparations should be used with caution and begin with the introduction of low doses, since the sensitivity of such patients to preparations of this pharmacotherapeutic class is often changed.

Treatment of patients with impaired renal and / or liver function. It may be necessary to reduce the dose of urapidil in patients with impaired renal and/or hepatic function.

duration of therapy. It has been established that parenteral therapy lasting 7 days is safe from a toxicological point of view. With parenteral administration of antihypertensive preparations, this period, as a rule, should not be exceeded.

With a repeated increase in blood pressure, it is possible to repeat the course of parenteral therapy.

You can start regular treatment with oral antihypertensive preparations during the course of emergency parenteral therapy with urapidil.

Contraindications

Hypersensitivity to urapidil or other components of the preparation, aortic stenosis, arteriovenous shunt (with the exception of a hemodynamically inactive shunt for dialysis).

Side effects

Most of the side effects are associated with too rapid a decrease in blood pressure. however, clinical experience indicates that these effects disappear after a few minutes, even during the infusion of the preparation, so the decision to stop therapy should be made depending on the severity of the undesirable effect. depending on the frequency, adverse reactions are divided into the following categories: very often (≥1/10), often (≥1/100, 1/10), infrequently (≥1/1000, 1/100), rarely (≥1/10 000, 1/1000), single (1/10,000).

From the blood and lymphatic system: single - thrombocytopenia.

From the side of the cardiovascular system: infrequently - palpitations, tachycardia, bradycardia, a feeling of pressure or pain behind the sternum (symptoms similar to angina pectoris), shortness of breath, arrhythmias, orthostatic dysregulation (decrease in blood pressure when changing body position, for example, getting up from a lying position) .

From the digestive tract: often - nausea; infrequently - vomiting.

General effects and local reactions: rarely - increased fatigue; single - asthenia.

From the nervous system: often - dizziness, headache.

On the part of the psyche: single - anxiety.

From the reproductive system and mammary glands: rarely - priapism.

On the part of the respiratory system, chest and mediastinal organs: rarely - nasal congestion.

From the side of the skin and subcutaneous tissues: infrequently - increased sweating; rarely - symptoms of skin allergic reactions (itching, rash, exanthema).

special instructions

It is necessary to use the preparation with caution:

• in heart failure caused by mechanical dysfunction of the heart, such as aortic or mitral valve stenosis, pulmonary embolism, or deterioration of cardiac function due to pericardial disease;
• in patients with impaired liver function;
• in patients with impaired renal function of moderate and severe degree;
• in elderly patients;
• with the simultaneous use of cimetidine (see INTERACTIONS).

If urapidil is not used as first-line antihypertensive therapy, sufficient time should elapse before starting treatment for the effect of previously prescribed antihypertensive preparations to end. In this case, therapy should be started with a low dose of urapidil. Too rapid a decrease in blood pressure can lead to bradycardia or cardiac arrest. Since Tachiben contains propylene glycol, the use of the preparation may cause symptoms similar to those when drinking alcohol. 1 dose of the preparation contains a small amount of sodium - <1 mmol (23 mg). Use during pregnancy and lactation. It is not recommended to use urapidil during pregnancy. Adequate data on the use of urapidil in pregnant women are not available. Animal studies have demonstrated urapidil's reproductive toxicity without evidence of teratogenicity. Given the limitations of these studies, the potential risk to humans is unknown. It is still unknown whether urapidil is excreted in breast milk, therefore, during treatment with the preparation, breastfeeding is recommended to stop. The ability to influence the reaction rate when driving vehicles or other mechanisms. In some cases, the preparation may slightly affect the ability to drive vehicles or other mechanisms. This is possible mainly at the beginning of treatment, when changing the treatment regimen or the simultaneous use of alcohol. Children. The safety and efficacy of intravenous urapidil in children (under 18 years of age) have not been established.

Interactions

the hypotensive effect of urapidil may be enhanced with simultaneous use with α-adrenergic blockers (including those used for urological indications), vasodilators and other antihypertensive preparations, as well as with hypovolemia (diarrhea, vomiting) and alcohol consumption. Urapidil should be used with caution in combination with baclofen, since baclofen may enhance the hypotensive effect. Cimetidine, when used simultaneously, inhibits the metabolism of urapidil. The concentration of urapidil in blood plasma can increase by 15%, therefore, in such cases, the advisability of dose reduction should be considered. Caution is required when using urapidil with the following preparations: imipramine (hypotensive effect and risk of orthostatic hypotension); neuroleptics (hypotensive effect and risk of orthostatic hypotension); corticosteroids (decrease in hypotensive effect due to sodium and water retention). Since there is not enough experience with combination therapy with ACE inhibitors, this combination is still not recommended. Incompatibility. The preparation should not be mixed with other preparations, with the exception of 0.9% sodium chloride solution for injection or 5% or 10% glucose solution for infusion. Do not use alkaline solutions for injection and infusion at the same time, as this may cause turbidity of the solution, the formation of flakes or sediment.

Overdose

symptoms: dizziness, orthostatic hypotension and collapse, as well as increased fatigue and lethargy. Overdose treatment: in case of an excessive decrease in blood pressure, it is necessary to give the patient a horizontal position with a low headboard and start infusion therapy to increase BCC. If these measures are not enough, slow vasoconstrictor preparations are administered intravenously under the control of blood pressure. In rare cases, the introduction of catecholamines (for example, epinephrine at a dose of 0.5–1.0 mg diluted in 10 ml of isotonic sodium chloride solution) may be required.

Storage conditions

at a temperature not exceeding 30 °C. Keep out of the reach of children.